CONGRESS ASSET MANAGEMENT CO /MA – Neurocrine Biosciences, Inc. Transaction History
CONGRESS ASSET MANAGEMENT CO /MA portfolio value:
$116.21M
portfolio value
CONGRESS ASSET MANAGEMENT CO /MA quarter portfolio value change:
+8.96%
quarter
Neurocrine Biosciences, Inc. 13F transactions
| Quarter | Transaction type | Change | Relative change | Absolute change | Change value | Avg. price | Shares |
|---|---|---|---|---|---|---|---|
| Q3 2022 | share | Increase | +1.89% | 20.33K shares | 11.53M | $106.21 | 1.09M |
| Q2 2022 | share | Decrease | -3.33% | -37.00K shares | 536K | $97.48 | 1.07M |
| Q1 2022 | share | Increase | +22.19% | 201.76K shares | 26.71M | $93.75 | 1.11M |
| Q4 2021 | share | Decrease | -10.15% | -102.68K shares | -19.61M | $84.63 | 909.08K |
| Q3 2021 | share | Increase | +6.66% | 63.20K shares | 4.72M | $95.91 | 1.01M |
| Q2 2021 | share | Increase | +5.18% | 46.73K shares | 4.61M | $97.32 | 948.56K |
| Q1 2021 | share | Increase | +18.52% | 140.89K shares | 14.76M | $97.25 | 901.83K |
| Q4 2020 | share | Decrease | -0.87% | -6.70K shares | -881K | $95.85 | 760.94K |
| Q3 2020 | share | Increase | 0.00% | 767.65K shares | 73.81M | $96.16 | 767.65K |